PubMed@pruas_18:32491073_en
Annnotations
ENG_NER_NEL
{"project":"ENG_NER_NEL","denotations":[{"id":"T2","span":{"begin":0,"end":11},"obj":"MESH:D017934"},{"id":"T3","span":{"begin":12,"end":19},"obj":"DOID:4"},{"id":"T4","span":{"begin":12,"end":19},"obj":"MESH:D004194"},{"id":"T5","span":{"begin":26,"end":34},"obj":"DOID:0080600"},{"id":"T7","span":{"begin":116,"end":124},"obj":"DOID:0080600"},{"id":"T13","span":{"begin":241,"end":249},"obj":"DOID:0080600"},{"id":"T15","span":{"begin":283,"end":294},"obj":"DOID:820"},{"id":"T16","span":{"begin":283,"end":294},"obj":"HP:0012819"},{"id":"T17","span":{"begin":283,"end":294},"obj":"MESH:D009205"},{"id":"T18","span":{"begin":331,"end":339},"obj":"MESH:D012106"},{"id":"T20","span":{"begin":377,"end":391},"obj":"CHEBI:35457"},{"id":"T21","span":{"begin":381,"end":391},"obj":"CHEBI:35222"},{"id":"T22","span":{"begin":396,"end":407},"obj":"CHEBI:2719"},{"id":"T23","span":{"begin":450,"end":462},"obj":"DOID:10763"},{"id":"T24","span":{"begin":450,"end":462},"obj":"HP:0000822"},{"id":"T25","span":{"begin":450,"end":462},"obj":"MESH:D006973"},{"id":"T27","span":{"begin":467,"end":472},"obj":"MESH:D006321"},{"id":"T28","span":{"begin":467,"end":480},"obj":"HP:0001635"},{"id":"T29","span":{"begin":467,"end":480},"obj":"MESH:D006333"},{"id":"T31","span":{"begin":484,"end":492},"obj":"DOID:0080600"},{"id":"T33","span":{"begin":504,"end":512},"obj":"MESH:D012106"},{"id":"T35","span":{"begin":562,"end":570},"obj":"DOID:0080600"}],"text":"Coronavirus disease 2019 (COVID-19) is a global pandemic affecting the world, seen in more than 1,300,000 patients. COVID-19 acts through the angiotensin-converting enzyme 2 (ACE2) receptor. Cardiovascular comorbidities are more common with COVID-19, and nearly 10% of cases develop myocarditis (22% of critical patients). Further research is needed to continue or discontinue ACE inhibitors and angiotensin receptor blockers, which are essential in hypertension and heart failure in COVID-19. Intensive research is promising for the treatment and prevention of COVID-19."}
test_lasige
{"project":"test_lasige","denotations":[{"id":"T2","span":{"begin":0,"end":11},"obj":"MESH:D017934"},{"id":"T4","span":{"begin":12,"end":19},"obj":"MESH:D004194"},{"id":"T3","span":{"begin":12,"end":19},"obj":"DOID:4"},{"id":"T5","span":{"begin":26,"end":34},"obj":"DOID:0080600"},{"id":"T7","span":{"begin":116,"end":124},"obj":"DOID:0080600"},{"id":"T13","span":{"begin":241,"end":249},"obj":"DOID:0080600"},{"id":"T17","span":{"begin":283,"end":294},"obj":"MESH:D009205"},{"id":"T16","span":{"begin":283,"end":294},"obj":"HP:0012819"},{"id":"T15","span":{"begin":283,"end":294},"obj":"DOID:820"},{"id":"T18","span":{"begin":331,"end":339},"obj":"MESH:D012106"},{"id":"T20","span":{"begin":377,"end":391},"obj":"CHEBI:35457"},{"id":"T21","span":{"begin":381,"end":391},"obj":"CHEBI:35222"},{"id":"T22","span":{"begin":396,"end":407},"obj":"CHEBI:2719"},{"id":"T25","span":{"begin":450,"end":462},"obj":"MESH:D006973"},{"id":"T24","span":{"begin":450,"end":462},"obj":"HP:0000822"},{"id":"T23","span":{"begin":450,"end":462},"obj":"DOID:10763"},{"id":"T29","span":{"begin":467,"end":480},"obj":"MESH:D006333"},{"id":"T28","span":{"begin":467,"end":480},"obj":"HP:0001635"},{"id":"T27","span":{"begin":467,"end":472},"obj":"MESH:D006321"},{"id":"T31","span":{"begin":484,"end":492},"obj":"DOID:0080600"},{"id":"T33","span":{"begin":504,"end":512},"obj":"MESH:D012106"},{"id":"T35","span":{"begin":562,"end":570},"obj":"DOID:0080600"}],"text":"Coronavirus disease 2019 (COVID-19) is a global pandemic affecting the world, seen in more than 1,300,000 patients. COVID-19 acts through the angiotensin-converting enzyme 2 (ACE2) receptor. Cardiovascular comorbidities are more common with COVID-19, and nearly 10% of cases develop myocarditis (22% of critical patients). Further research is needed to continue or discontinue ACE inhibitors and angiotensin receptor blockers, which are essential in hypertension and heart failure in COVID-19. Intensive research is promising for the treatment and prevention of COVID-19."}
ENG_NER_NEL_mabarros
{"project":"ENG_NER_NEL_mabarros","denotations":[{"id":"T13","span":{"begin":241,"end":249},"obj":"DOID:0080600"},{"id":"T15","span":{"begin":283,"end":294},"obj":"DOID:820"},{"id":"T16","span":{"begin":283,"end":294},"obj":"HP:0012819"},{"id":"T17","span":{"begin":283,"end":294},"obj":"MESH:D009205"},{"id":"T18","span":{"begin":331,"end":339},"obj":"MESH:D012106"},{"id":"T2","span":{"begin":0,"end":11},"obj":"MESH:D017934"},{"id":"T20","span":{"begin":377,"end":391},"obj":"CHEBI:35457"},{"id":"T21","span":{"begin":381,"end":391},"obj":"CHEBI:35222"},{"id":"T22","span":{"begin":396,"end":407},"obj":"CHEBI:2719"},{"id":"T23","span":{"begin":450,"end":462},"obj":"DOID:10763"},{"id":"T24","span":{"begin":450,"end":462},"obj":"HP:0000822"},{"id":"T25","span":{"begin":450,"end":462},"obj":"MESH:D006973"},{"id":"T27","span":{"begin":467,"end":472},"obj":"MESH:D006321"},{"id":"T28","span":{"begin":467,"end":480},"obj":"HP:0001635"},{"id":"T29","span":{"begin":467,"end":480},"obj":"MESH:D006333"},{"id":"T3","span":{"begin":12,"end":19},"obj":"DOID:4"},{"id":"T31","span":{"begin":484,"end":492},"obj":"DOID:0080600"},{"id":"T33","span":{"begin":504,"end":512},"obj":"MESH:D012106"},{"id":"T35","span":{"begin":562,"end":570},"obj":"DOID:0080600"},{"id":"T4","span":{"begin":12,"end":19},"obj":"MESH:D004194"},{"id":"T5","span":{"begin":26,"end":34},"obj":"DOID:0080600"},{"id":"T7","span":{"begin":116,"end":124},"obj":"DOID:0080600"}],"text":"Coronavirus disease 2019 (COVID-19) is a global pandemic affecting the world, seen in more than 1,300,000 patients. COVID-19 acts through the angiotensin-converting enzyme 2 (ACE2) receptor. Cardiovascular comorbidities are more common with COVID-19, and nearly 10% of cases develop myocarditis (22% of critical patients). Further research is needed to continue or discontinue ACE inhibitors and angiotensin receptor blockers, which are essential in hypertension and heart failure in COVID-19. Intensive research is promising for the treatment and prevention of COVID-19."}
ENG_NER_NEL_Diana
{"project":"ENG_NER_NEL_Diana","denotations":[{"id":"T2","span":{"begin":0,"end":11},"obj":"MESH:D017934"},{"id":"T3","span":{"begin":12,"end":19},"obj":"DOID:4"},{"id":"T4","span":{"begin":12,"end":19},"obj":"MESH:D004194"},{"id":"T5","span":{"begin":26,"end":34},"obj":"DOID:0080600"},{"id":"T7","span":{"begin":116,"end":124},"obj":"DOID:0080600"},{"id":"T13","span":{"begin":241,"end":249},"obj":"DOID:0080600"},{"id":"T15","span":{"begin":283,"end":294},"obj":"DOID:820"},{"id":"T16","span":{"begin":283,"end":294},"obj":"HP:0012819"},{"id":"T17","span":{"begin":283,"end":294},"obj":"MESH:D009205"},{"id":"T18","span":{"begin":331,"end":339},"obj":"MESH:D012106"},{"id":"T20","span":{"begin":377,"end":391},"obj":"CHEBI:35457"},{"id":"T21","span":{"begin":381,"end":391},"obj":"CHEBI:35222"},{"id":"T22","span":{"begin":396,"end":407},"obj":"CHEBI:2719"},{"id":"T23","span":{"begin":450,"end":462},"obj":"DOID:10763"},{"id":"T24","span":{"begin":450,"end":462},"obj":"HP:0000822"},{"id":"T25","span":{"begin":450,"end":462},"obj":"MESH:D006973"},{"id":"T27","span":{"begin":467,"end":472},"obj":"MESH:D006321"},{"id":"T28","span":{"begin":467,"end":480},"obj":"HP:0001635"},{"id":"T29","span":{"begin":467,"end":480},"obj":"MESH:D006333"},{"id":"T31","span":{"begin":484,"end":492},"obj":"DOID:0080600"},{"id":"T33","span":{"begin":504,"end":512},"obj":"MESH:D012106"},{"id":"T35","span":{"begin":562,"end":570},"obj":"DOID:0080600"}],"text":"Coronavirus disease 2019 (COVID-19) is a global pandemic affecting the world, seen in more than 1,300,000 patients. COVID-19 acts through the angiotensin-converting enzyme 2 (ACE2) receptor. Cardiovascular comorbidities are more common with COVID-19, and nearly 10% of cases develop myocarditis (22% of critical patients). Further research is needed to continue or discontinue ACE inhibitors and angiotensin receptor blockers, which are essential in hypertension and heart failure in COVID-19. Intensive research is promising for the treatment and prevention of COVID-19."}
ENG_NER_NEL_pruas
{"project":"ENG_NER_NEL_pruas","denotations":[{"id":"T13","span":{"begin":241,"end":249},"obj":"DOID:0080600"},{"id":"T15","span":{"begin":283,"end":294},"obj":"DOID:820"},{"id":"T16","span":{"begin":283,"end":294},"obj":"HP:0012819"},{"id":"T17","span":{"begin":283,"end":294},"obj":"MESH:D009205"},{"id":"T20","span":{"begin":377,"end":391},"obj":"CHEBI:35457"},{"id":"T22","span":{"begin":396,"end":425},"obj":"CHEBI:61016"},{"id":"T23","span":{"begin":450,"end":462},"obj":"DOID:10763"},{"id":"T24","span":{"begin":450,"end":462},"obj":"HP:0000822"},{"id":"T25","span":{"begin":450,"end":462},"obj":"MESH:D006973"},{"id":"T27","span":{"begin":467,"end":472},"obj":"MESH:D006321"},{"id":"T28","span":{"begin":467,"end":480},"obj":"HP:0001635"},{"id":"T29","span":{"begin":467,"end":480},"obj":"MESH:D006333"},{"id":"T31","span":{"begin":484,"end":492},"obj":"DOID:0080600"},{"id":"T33","span":{"begin":504,"end":512},"obj":"MESH:D012106"},{"id":"T35","span":{"begin":562,"end":570},"obj":"DOID:0080600"},{"id":"T36","span":{"begin":0,"end":24},"obj":"DOID:0080600"},{"id":"T37","span":{"begin":142,"end":189},"obj":"MESH:D011945"},{"id":"T38","span":{"begin":191,"end":219},"obj":"HP:0001626"},{"id":"T5","span":{"begin":26,"end":34},"obj":"DOID:0080600"},{"id":"T7","span":{"begin":116,"end":124},"obj":"DOID:0080600"},{"id":"T39","span":{"begin":0,"end":24},"obj":"MESH:D000086382"},{"id":"T40","span":{"begin":26,"end":34},"obj":"MESH:D000086382"},{"id":"T41","span":{"begin":116,"end":124},"obj":"MESH:D000086382"},{"id":"T42","span":{"begin":241,"end":249},"obj":"MESH:D000086382"},{"id":"T43","span":{"begin":562,"end":570},"obj":"MESH:D000086382"},{"id":"T44","span":{"begin":484,"end":492},"obj":"MESH:D000086382"}],"text":"Coronavirus disease 2019 (COVID-19) is a global pandemic affecting the world, seen in more than 1,300,000 patients. COVID-19 acts through the angiotensin-converting enzyme 2 (ACE2) receptor. Cardiovascular comorbidities are more common with COVID-19, and nearly 10% of cases develop myocarditis (22% of critical patients). Further research is needed to continue or discontinue ACE inhibitors and angiotensin receptor blockers, which are essential in hypertension and heart failure in COVID-19. Intensive research is promising for the treatment and prevention of COVID-19."}